WO2003027085A3 - 3-pyridyl or 4-isoquinolinyl thiazoles as c17,20 lyase inhibitors - Google Patents

3-pyridyl or 4-isoquinolinyl thiazoles as c17,20 lyase inhibitors Download PDF

Info

Publication number
WO2003027085A3
WO2003027085A3 PCT/US2002/030483 US0230483W WO03027085A3 WO 2003027085 A3 WO2003027085 A3 WO 2003027085A3 US 0230483 W US0230483 W US 0230483W WO 03027085 A3 WO03027085 A3 WO 03027085A3
Authority
WO
WIPO (PCT)
Prior art keywords
pyridyl
thiazoles
isoquinolinyl
cancer
lyase inhibitors
Prior art date
Application number
PCT/US2002/030483
Other languages
French (fr)
Other versions
WO2003027085A2 (en
Inventor
Donald Bierer
Andrea Mcclure
Wenlang Fu
Furahi Achebe
Gaetan H Ladouceur
Michael J Burke
Cheng Bi
Barry Hart
Jacques Dumas
Robert Sibley
William J Scott
Jeffrey Johnson
Davoud Asgari
Original Assignee
Bayer Pharmaceuticals Corp
Donald Bierer
Andrea Mcclure
Wenlang Fu
Furahi Achebe
Gaetan H Ladouceur
Michael J Burke
Cheng Bi
Barry Hart
Jacques Dumas
Robert Sibley
William J Scott
Jeffrey Johnson
Davoud Asgari
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp, Donald Bierer, Andrea Mcclure, Wenlang Fu, Furahi Achebe, Gaetan H Ladouceur, Michael J Burke, Cheng Bi, Barry Hart, Jacques Dumas, Robert Sibley, William J Scott, Jeffrey Johnson, Davoud Asgari filed Critical Bayer Pharmaceuticals Corp
Priority to AU2002362603A priority Critical patent/AU2002362603A1/en
Priority to US10/490,822 priority patent/US20040267017A1/en
Priority to EP02799636A priority patent/EP1432706A2/en
Priority to CA002461360A priority patent/CA2461360A1/en
Priority to JP2003530675A priority patent/JP2005532983A/en
Publication of WO2003027085A2 publication Critical patent/WO2003027085A2/en
Publication of WO2003027085A3 publication Critical patent/WO2003027085A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Abstract

The invention provides novel thiazoles bearing 3-pyridyl or 4-isoquinilinyl substituents, and pharmaceutical compositions thereof. The invention also provides methods of using compounds of the invention and pharmaceutical compositions thereof as inhibitors of lyases, e.g., the 17a-hydroxylase-C17,20 enzyme. The invention further provides methods for treating cancer in a subject, comprising administering to the subject a compound of the invention or a pharmaceutical composition thereof. The cancer can be, e.g., prostate cancer or breast cancer.
PCT/US2002/030483 2001-09-26 2002-09-26 3-pyridyl or 4-isoquinolinyl thiazoles as c17,20 lyase inhibitors WO2003027085A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2002362603A AU2002362603A1 (en) 2001-09-26 2002-09-26 3-pyridyl or 4-isoquinolinyl thiazoles as c17,20 lyase inhibitors
US10/490,822 US20040267017A1 (en) 2001-09-26 2002-09-26 3-pyridyl or 4-isoquinolinyl thiazoles as c17, 20 lyase inhibitors
EP02799636A EP1432706A2 (en) 2001-09-26 2002-09-26 3-pyridyl or 4-isoquinolinyl thiazoles as c17,20 lyase inhibitors
CA002461360A CA2461360A1 (en) 2001-09-26 2002-09-26 3-pyridyl or 4-isoquinolinyl thiazoles as c17,20 lyase inhibitors
JP2003530675A JP2005532983A (en) 2001-09-26 2002-09-26 3-Pyridyl or 4-isoquinolinyl thiazole as C17,20 lyase inhibitor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32499301P 2001-09-26 2001-09-26
US60/324,993 2001-09-26

Publications (2)

Publication Number Publication Date
WO2003027085A2 WO2003027085A2 (en) 2003-04-03
WO2003027085A3 true WO2003027085A3 (en) 2003-12-04

Family

ID=23265979

Family Applications (8)

Application Number Title Priority Date Filing Date
PCT/US2002/030482 WO2003027094A2 (en) 2001-09-26 2002-09-26 Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors
PCT/US2002/030983 WO2003027096A1 (en) 2001-09-26 2002-09-26 Substituted 3-pyridyl imidazoles as c17,20 lyase inhibitors
PCT/US2002/030981 WO2003027105A1 (en) 2001-09-26 2002-09-26 Substituted 3-pyridyl thiophenes as c17,20 lyase inhibitors
PCT/US2002/030834 WO2003027107A1 (en) 2001-09-26 2002-09-26 Substituted 3-pyridyl oxazoles as c17,20 lyase inhibitors
PCT/US2002/030979 WO2003027101A1 (en) 2001-09-26 2002-09-26 Substituted 3-pyridyl pyrroles and 3-pyridyl pyrazoles as c17,20 lyase inhibitors
PCT/US2002/030924 WO2003027100A1 (en) 2001-09-26 2002-09-26 Substituted 3-pyridyl pyrimidines as c17,20 lyase inhibitors
PCT/US2002/030982 WO2003027095A1 (en) 2001-09-26 2002-09-26 Substituted 3-pyridyl tetrazoles as steroid c17,20 lyase inhibitors
PCT/US2002/030483 WO2003027085A2 (en) 2001-09-26 2002-09-26 3-pyridyl or 4-isoquinolinyl thiazoles as c17,20 lyase inhibitors

Family Applications Before (7)

Application Number Title Priority Date Filing Date
PCT/US2002/030482 WO2003027094A2 (en) 2001-09-26 2002-09-26 Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors
PCT/US2002/030983 WO2003027096A1 (en) 2001-09-26 2002-09-26 Substituted 3-pyridyl imidazoles as c17,20 lyase inhibitors
PCT/US2002/030981 WO2003027105A1 (en) 2001-09-26 2002-09-26 Substituted 3-pyridyl thiophenes as c17,20 lyase inhibitors
PCT/US2002/030834 WO2003027107A1 (en) 2001-09-26 2002-09-26 Substituted 3-pyridyl oxazoles as c17,20 lyase inhibitors
PCT/US2002/030979 WO2003027101A1 (en) 2001-09-26 2002-09-26 Substituted 3-pyridyl pyrroles and 3-pyridyl pyrazoles as c17,20 lyase inhibitors
PCT/US2002/030924 WO2003027100A1 (en) 2001-09-26 2002-09-26 Substituted 3-pyridyl pyrimidines as c17,20 lyase inhibitors
PCT/US2002/030982 WO2003027095A1 (en) 2001-09-26 2002-09-26 Substituted 3-pyridyl tetrazoles as steroid c17,20 lyase inhibitors

Country Status (5)

Country Link
EP (2) EP1432706A2 (en)
JP (2) JP2005528325A (en)
AU (2) AU2002340010A1 (en)
CA (2) CA2461363A1 (en)
WO (8) WO2003027094A2 (en)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002221080A1 (en) * 2000-12-08 2002-06-18 Masami Kusaka Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparingthe same and use thereof
JP4160295B2 (en) * 2000-12-08 2008-10-01 武田薬品工業株式会社 Substituted thiazole derivatives having a 3-pyridyl group, method for producing the same, and use thereof
US20040147561A1 (en) * 2002-12-27 2004-07-29 Wenge Zhong Pyrid-2-one derivatives and methods of use
AU2004247013B2 (en) * 2003-05-14 2010-07-08 Neurogenetic Pharmaceuticals, Inc. Compounds and uses thereof in modulating amyloid beta
ES2222827B1 (en) * 2003-07-30 2006-03-01 Laboratorios Del Dr. Esteve, S.A. DERIVATIVES OF 5-INDOLILSULFONAMIDS, ITS PREPARATION AND ITS APPLICATION AS MEDICINES.
CN1925854A (en) * 2003-11-14 2007-03-07 沃泰克斯药物股份有限公司 Thiazoles and oxazoles useful as modulators of ATP-binding cassette transporters
ATE485824T1 (en) 2004-04-13 2010-11-15 Icagen Inc POLYCYCLIC PYRIMIDINES AS POTASSIUM ION CHANNEL MODULATORS
JP4602686B2 (en) * 2004-04-15 2010-12-22 広栄化学工業株式会社 Process for producing 2,6-dihalogeno-4-arylpyridines
EP1812071A2 (en) * 2004-10-13 2007-08-01 PTC Therapeutics, Inc. Compounds for nonsense suppression, use of these compounds for the manufacture of a medicament for treating somatic mutation-related diseases
KR101318012B1 (en) * 2004-10-20 2013-10-14 메르크 세로노 에스.에이. 3-arylamino pyridine derivatives
WO2006051723A1 (en) * 2004-11-09 2006-05-18 Kaneka Corporation Method for producing 1-halo-3-aryl-2-propanone
GB0428514D0 (en) * 2004-12-31 2005-02-09 Prosidion Ltd Compounds
US8097623B2 (en) * 2005-01-19 2012-01-17 Biolipox Ab Indoles useful in the treatment of inflammation
UA92746C2 (en) 2005-05-09 2010-12-10 Акилайон Фармасьютикалз, Инк. Thiazole compounds and methods of use
EA016300B1 (en) * 2005-07-29 2012-04-30 4ЭсЦэ АГ NOVEL HETEROCYCLIC NF-κB INHIBITORS
FR2889526B1 (en) * 2005-08-04 2012-02-17 Aventis Pharma Sa SUBSTITUTED 7-AZA-INDAZOLES, COMPOSITIONS CONTAINING SAME, PROCESS FOR PRODUCTION AND USE
CN101282936B (en) * 2005-10-07 2012-05-16 橘生药品工业株式会社 Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same
TWI385169B (en) 2005-10-31 2013-02-11 Eisai R&D Man Co Ltd Heterocyclic substituted pyridine derivatives and antifungal agent containing same
AR056893A1 (en) * 2005-12-28 2007-10-31 Takeda Pharmaceutical FUSIONED AND FUSIONED HETEROCICLIC COMPOUNDS, MINERALOCORTICOID RECEPTORS ANTAGONISTS
KR101081293B1 (en) * 2006-01-18 2011-11-08 에프. 호프만-라 로슈 아게 Thiazoles as 11 beta-hsd1 inhibitors
AU2007208109B2 (en) 2006-01-24 2012-08-23 Eli Lilly And Company Indole sulfonamide modulators of progesterone receptors
BRPI0709633B8 (en) 2006-03-29 2021-05-25 Hoffmann La Roche pyridine and pyrimidine derivatives as mglur2 antagonists, pharmaceutical composition and their use
WO2008021337A1 (en) 2006-08-15 2008-02-21 Wyeth Oxazinan-2-one derivatives useful as pr modulators
WO2008021338A2 (en) 2006-08-15 2008-02-21 Wyeth Tricyclic oxazolidone derivatives useful as pr modulators
WO2008021309A1 (en) 2006-08-15 2008-02-21 Wyeth Imidazolidin-2-one derivatives useful as pr modulators
US7649007B2 (en) 2006-08-15 2010-01-19 Wyeth Llc Oxazolidine derivatives as PR modulators
JP5284788B2 (en) * 2006-09-21 2013-09-11 エーザイ・アール・アンド・ディー・マネジメント株式会社 Heteroaryl ring-substituted pyridine derivatives and antifungal agents containing them
US8183264B2 (en) 2006-09-21 2012-05-22 Eisai R&D Managment Co., Ltd. Pyridine derivative substituted by heteroaryl ring, and antifungal agent comprising the same
ZA200902127B (en) 2006-10-02 2010-07-28 Cortendo Invest Ab Ketoconazole enantiomer in humans
WO2008070350A2 (en) 2006-10-27 2008-06-12 The Board Of Regents Of The University Of Texas System Methods and compositions related to wrapping of dehydrons
US9187485B2 (en) 2007-02-02 2015-11-17 Baylor College Of Medicine Methods and compositions for the treatment of cancer and related hyperproliferative disorders
EA200901573A1 (en) 2007-05-22 2010-04-30 Ачиллион Фармасьютикалз, Инк. Heteroaryl Thiazole Substituents
BR122018001851B1 (en) 2007-08-13 2019-08-20 Monsanto Technology Llc PLANT PARASITE NEMATOID CONTROL METHOD
AU2008310097B2 (en) 2007-10-09 2013-05-16 Merck Patent Gmbh Pyridine derivatives useful as glucokinase activators
US8513287B2 (en) 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
PL2231642T3 (en) * 2008-01-11 2014-04-30 Novartis Ag Pyrimidines as kinase inhibitors
US9029411B2 (en) 2008-01-25 2015-05-12 Millennium Pharmaceuticals, Inc. Thiophenes and uses thereof
CN101965176B (en) 2008-02-08 2012-06-20 株式会社资生堂 Whitening agent and skin external preparation
ES2927660T3 (en) * 2008-06-16 2022-11-10 Univ Tennessee Res Found Compounds for the treatment of cancer
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
TWI409265B (en) * 2008-08-20 2013-09-21 Merck Sharp & Dohme Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
PE20110843A1 (en) 2008-09-22 2011-12-08 Cayman Chem Co DERIVATIVES OF 5- (1H-IMIDAZOL-5-IL) -2-PHENYLPYRIMIDINE, AS INHIBITORS OF PROSTAGLANDIN D HEMATOPOYETIC SYNTHASE
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
CN102395585A (en) 2009-01-30 2012-03-28 米伦纽姆医药公司 Heteroaryls and their use as pi3k inhibitors
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
TW201038553A (en) * 2009-03-19 2010-11-01 Sanofi Aventis Novel indazole derivatives which inhibit HSP90, compositions containing them and use thereof
EP2597089A1 (en) * 2009-10-29 2013-05-29 Bristol-Myers Squibb Company Tricyclic heterocyclic compounds
WO2011051198A2 (en) * 2009-10-30 2011-05-05 Bayer Cropscience Ag Pyridine derivatives as agricultural pesticides
DE102009058280A1 (en) 2009-12-14 2011-06-16 Merck Patent Gmbh thiazole
KR20120130777A (en) 2010-03-01 2012-12-03 유니버시티 오브 테네시 리서치 파운데이션 Compounds for treatment of cancer
JP2013534539A (en) 2010-07-15 2013-09-05 ブリストル−マイヤーズ スクイブ カンパニー Azaindazole compounds
WO2012018948A2 (en) 2010-08-04 2012-02-09 Pellficure Pharmaceuticals, Inc. Novel treatment of prostate carcinoma
US9062038B2 (en) 2010-08-11 2015-06-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
JP2013533318A (en) 2010-08-11 2013-08-22 ミレニアム ファーマシューティカルズ， インコーポレイテッド Heteroaryl and uses thereof
PE20131304A1 (en) 2010-08-11 2013-11-14 Millennium Pharm Inc HETEROARYLS AND THEIR USES
UY33671A (en) 2010-10-13 2012-04-30 Millenium Pharmaceuticals Inc HETEROARILOS AND ITS USES
EP2630133A1 (en) * 2010-10-22 2013-08-28 Bayer Intellectual Property GmbH Novel heterocyclic compounds as pesticides
AU2011320565A1 (en) * 2010-10-28 2013-05-23 Innocrin Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
CN103328473A (en) 2010-11-12 2013-09-25 百时美施贵宝公司 Substituted azaindazole compounds
GB2485404A (en) * 2010-11-15 2012-05-16 Nat Univ Ireland Metal-complexed pyridyl-substituted tetrazole compounds and their use in treating cancer
CN102675286B (en) * 2011-03-07 2015-08-19 中国科学院上海药物研究所 One class indazole compounds and preparation method thereof, purposes and pharmaceutical composition
EP2702052B1 (en) * 2011-04-28 2017-10-18 Novartis AG 17alpha-hydroxylase/c17,20-lyase inhibitors
WO2012162468A1 (en) * 2011-05-25 2012-11-29 Janssen Pharmaceutica Nv Thiazol derivatives as pro -matrix metalloproteinase inhibitors
EP2760870B1 (en) 2011-09-27 2016-05-04 Bristol-Myers Squibb Company Substituted bicyclic heteroaryl compounds
WO2014055595A1 (en) 2012-10-05 2014-04-10 Merck Sharp & Dohme Corp. Indoline compounds as aldosterone synthase inhibitiors related applications
WO2014099833A1 (en) * 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Indazole compounds as aldosterone synthase inhibitors
JP6835472B2 (en) 2013-03-05 2021-02-24 ユニバーシティ オブ テネシー リサーチ ファウンデーション Compositions for the treatment of cancer
US20160022606A1 (en) 2013-03-14 2016-01-28 Pellficure Pharmaceuticals Inc. Novel therapy for prostate carcinoma
US10093620B2 (en) 2014-09-12 2018-10-09 Pellficure Pharmaceuticals, Inc. Compositions and methods for treatment of prostate carcinoma
EP3528799A1 (en) 2016-10-24 2019-08-28 Pellficure Pharmaceuticals, Inc. Pharmaceutical compositions of 5-hydroxy-2-methylnaphthalene-1, 4-dione
JP7193071B2 (en) * 2017-02-08 2022-12-20 国立大学法人東海国立大学機構 Fluorescent materials and UV absorbers
EP4077332A4 (en) * 2019-12-18 2024-05-01 Univ California Inhibitors of lin28 and methods of use thereof
US20210246109A1 (en) * 2020-02-11 2021-08-12 University Of Kentucky Research Foundation Potent and selective inhibitors of cytochrome p450
WO2023049199A1 (en) * 2021-09-24 2023-03-30 Zeno Management, Inc. Azole compounds

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2022085A (en) * 1978-06-02 1979-12-12 Pfizer Novel Aminothiazoles
JPS55133366A (en) * 1979-04-05 1980-10-17 Otsuka Pharmaceut Factory Inc Thiazole derivative
JPH04154773A (en) * 1990-10-15 1992-05-27 Green Cross Corp:The Thiazole derivative
EP0790057A1 (en) * 1994-11-29 1997-08-20 Hisamitsu Pharmaceutical Co., Inc. Antibacterial or bactericide comprising 2-aminothiazole derivative and salts thereof
WO1999058511A1 (en) * 1998-05-12 1999-11-18 American Home Products Corporation Oxazole-aryl-carboxylic acids useful in the treatment of insulin resistance and hyperglycemia
WO2001064674A1 (en) * 2000-03-01 2001-09-07 Janssen Pharmaceutica N.V. 2,4-disubstituted thiazolyl derivatives

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4536505A (en) * 1983-05-17 1985-08-20 Ciba-Geigy Corporation Certain N-(pyridyl) indoles
DE3940476A1 (en) * 1989-12-07 1991-06-13 Bayer Ag PYRIDINYLPYRIMIDINE DERIVATIVES
DE3940477A1 (en) * 1989-12-07 1991-06-13 Bayer Ag HETARYL-SUBSTITUTED PYRIDINYLPYRIMIDINE DERIVATIVES
DE4117560A1 (en) * 1991-05-29 1992-12-03 Bayer Ag USE OF PYRIDINYLPYRIMIDINE DERIVATIVES TO PROTECT TECHNICAL MATERIALS
TW223004B (en) * 1991-11-25 1994-05-01 Sumitomo Chemical Co
US5395817A (en) * 1992-01-22 1995-03-07 Imperial Chemical Industries Plc N-arylindoles and their use as herbicides
US5599774A (en) * 1992-01-22 1997-02-04 Imperial Chemical Industries Plc N-arylindoles and their use as herbicides
PT630367E (en) * 1992-03-09 2000-10-31 Zeneca Ltd NEW ARILINDAZOLES AND ITS USE AS HERBICIDES
US5444038A (en) * 1992-03-09 1995-08-22 Zeneca Limited Arylindazoles and their use as herbicides
US6046136A (en) * 1997-06-24 2000-04-04 Zeneca Limited Herbicidal heterocyclic N-oxides compounds
US5840721A (en) * 1997-07-09 1998-11-24 Ontogen Corporation Imidazole derivatives as MDR modulators
WO1999018099A1 (en) * 1997-10-03 1999-04-15 Merck Frosst Canada & Co. Aryl thiophene derivatives as pde iv inhibitors
AU5227999A (en) * 1998-07-27 2000-02-21 Abbott Laboratories Substituted oxazolines as antiproliferative agents

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2022085A (en) * 1978-06-02 1979-12-12 Pfizer Novel Aminothiazoles
JPS55133366A (en) * 1979-04-05 1980-10-17 Otsuka Pharmaceut Factory Inc Thiazole derivative
JPH04154773A (en) * 1990-10-15 1992-05-27 Green Cross Corp:The Thiazole derivative
EP0790057A1 (en) * 1994-11-29 1997-08-20 Hisamitsu Pharmaceutical Co., Inc. Antibacterial or bactericide comprising 2-aminothiazole derivative and salts thereof
WO1999058511A1 (en) * 1998-05-12 1999-11-18 American Home Products Corporation Oxazole-aryl-carboxylic acids useful in the treatment of insulin resistance and hyperglycemia
WO2001064674A1 (en) * 2000-03-01 2001-09-07 Janssen Pharmaceutica N.V. 2,4-disubstituted thiazolyl derivatives

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DN GRIGORYEV, BJ LONG, IP NANE,VCO NJAR, Y LIU AND AMH BRODIE: "Effects of new 17alpha-hydroxylase/C17,20-lyase inhibitors on LNCaP prostate cancer cell growth in vitro and in vivo", BRITISH JOURNAL OF CANCER, vol. 81, no. 4, 1999, pages 622 - 630, XP009001303 *
PATENT ABSTRACTS OF JAPAN *
YAN ZHUANG AND ROLF W. HARTMANN: "Synthesis and Evaluation of Azole-substituted 2-Aryl-6-methoxy-3,4-dihydronaphthalenes and -naphthalenes as Inhibitors of 17 alpha-Hydroxylase-C17,20-Lyase (P450 17)", ARCH. PHARM. PHARM. MED. CHEM., vol. 332, 1999, pages 25 - 30, XP002222972 *

Also Published As

Publication number Publication date
WO2003027095A1 (en) 2003-04-03
CA2461360A1 (en) 2003-04-03
JP2005528325A (en) 2005-09-22
EP1432706A2 (en) 2004-06-30
WO2003027096A1 (en) 2003-04-03
AU2002362603A1 (en) 2003-04-07
AU2002340010A1 (en) 2003-04-07
WO2003027107A1 (en) 2003-04-03
CA2461363A1 (en) 2003-04-03
WO2003027105A1 (en) 2003-04-03
WO2003027100A1 (en) 2003-04-03
WO2003027085A2 (en) 2003-04-03
WO2003027094A2 (en) 2003-04-03
EP1432698A2 (en) 2004-06-30
WO2003027101A1 (en) 2003-04-03
WO2003027094A3 (en) 2003-10-23
JP2005532983A (en) 2005-11-04

Similar Documents

Publication Publication Date Title
WO2003027085A3 (en) 3-pyridyl or 4-isoquinolinyl thiazoles as c17,20 lyase inhibitors
HK1065033A1 (en) Thiazole compounds useful as inhibitors or proteinkinases
MXPA03010961A (en) Thiazole compounds useful as inhibitors of protein kinases.
GEP20094666B (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
EP1622616A4 (en) Inhibitors of akt activity
MX2007007919A (en) Novel benzylamine derivatives as cetp inhibitors.
HK1087700A1 (en) Triazolopyridazines as protein kinases inhibitors
MXPA05005223A (en) Diaminotriazoles useful as inhibitors of protein kinases.
WO2007106192A3 (en) Inhibitors of iap
GEP20053424B (en) Pyrimidine-2,4,6-Trione Metalloproteinase Inhibitors
WO2004080418A3 (en) Nucleic acid compounds for inhibiting angiogenesis and tumor growth
AU2002314914A1 (en) Hydroxy alkyl amine derivatives as beta-secretase inhibitors and their use for the treatment of alzheimer's disease and similar diseases
WO2002009684A3 (en) ERBB-2 selective small molecule kinase inhibitors
WO2000004954A3 (en) Novel urokinase inhibitors
WO2004030620A3 (en) Novel tyrosine kinase inhibitors
TW200740812A (en) 1,4-Dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them
DE60019586D1 (en) MYOSTATIN GENPROMOTER AND INHIBITION OF ITS ACTIVATION
WO2004032908A3 (en) Method of inhibiting angiogenesis
WO2005030209A8 (en) Pyridine derivatives and use thereof as urotensin ii antagonists
MY130792A (en) 17ß-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES
MXPA03001356A (en) Novel beta-amyloid inhibitors, method for producing the same and the use thereof as medicaments.
MXPA05006507A (en) Inhibitors of the binding of chemokines i-tac or sdf-1 to the ccxckr2 receptor.
CY1111289T1 (en) COMPOSITIONS OF VOLUME INHIBITORS CONTAINING NITROACRIDINE
HK1074840A1 (en) Novel dithiolopyrrolones with therapeutic activity
WO2004060878A3 (en) Inhibitors of phosphatases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002799636

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2461360

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003530675

Country of ref document: JP

Ref document number: 10490822

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2002799636

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002799636

Country of ref document: EP